Specific biomarkers such as SFMBT2, ITGA4, THBD, and ZNF304 have emerged as critical indicators for early CRC screening at the tissue level, while methylation patterns of genes like KCNJ12, VAV3-AS1, and EVC are being employed to stage CRC accurately.410 Additionally, methylation anomalies in SEPT9 and SDC2 detected in fecal samples are proving to be effective for non-invasive early detection of CRC.411 The therapeutic landscape is also evolving with the proposal to use DNA methyltransferase inhibitors to target methylation abnormalities in CRC treatment strategies. This evidence concerns the gene ZNF304 and colorectal carcinoma.